Perspectives of Ketamine Use in COVID-19 Patients
Autor: | Avi A. Weinbroum |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Critical Care Sedation media_common.quotation_subject Psychological intervention Anxiety Brief Communication Suicidal Ideation 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Intensive care medicine Humans Hypnotics and Sedatives Anesthesia Ketamine 030212 general & internal medicine Intensive care medicine Suicidal ideation Depression (differential diagnoses) media_common Depression business.industry Hemodynamics COVID-19 General Medicine COVID-19 Drug Treatment Hospitalization Sadness Anesthesiology & Pain Medicine Treatment Outcome Immune System medicine.symptom Respiratory Insufficiency business Stress Psychological medicine.drug |
Zdroj: | Journal of Korean Medical Science |
ISSN: | 1598-6357 1011-8934 |
Popis: | Hospitalized coronavirus disease 2019 (COVID-19)-infected patients suffer from both physical impairments and mental stress. Respiratory insufficiency and cardiovascular disturbances require most of the intensive care interventions, but they are also accompanied by depressive conditions, sadness and fear of dying. Sedatives are mostly respiratory and cardiovascular depressants and do not provide resistance to the pro-inflammatory burst induced by the virus. Ketamine is a unique and safe drug that enables well-controlled sedation and anesthesia, attenuates depression and mitigates suicidal thoughts, without depressing respiratory or cardiovascular mechanics. This brief communication highlights the benefits potentially provided by ketamine to patients hospitalized for COVID-19 infection. Graphical Abstract |
Databáze: | OpenAIRE |
Externí odkaz: |